Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Fixed-Duration Zanubrutinib and Sonrotoclax (Z+S) All-Oral Combination Therapy in CLL/SLL Patients in 1st Relapse After Initial Fixed-Duration Novel Therapy (ZeuS-2 Trial)

NCT07812246 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT07812246
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07812246 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Fixed-Duration Zanubrutinib and Sonrotoclax (Z+S) All-Oral Combination Therapy in CLL/SLL Patients in 1st Relapse After Initial Fixed-Duration Novel Therapy (ZeuS-2 Trial)
Lead sponsor
City of Hope Medical Center
Phase
Phase 2
Overall status
Not yet recruiting
Start date
August 4, 2027
Completion date
August 13, 2028
Enrollment
44 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent chronic lymphocytic leukemia/small lymphocytic lymphoma